Table 1: Baseline characteristics of NSCLC patients with/without BM.

 

 

Without BM (N=255)

With BM  (n=52)

p

Age (year)

Median (range)

62 (25-83)

62.5 (43-78)

0.92

BMI (kg/m²)

Median (range)

23.18 (16-34)

22.85 (14-30)

0.088

Sex

Male (%)

154 (60.4%)

31 (59.6%)

0.92

Smoking

Yes (%)

157 (61.6%)

35 (67.3%)

0.436

Hypertension

Yes (%)

105 (41.2%)

25 (48.1%)

0.359

Diabetes

Yes (%)

59 (23.1%)

9 (17.3%)

0.37

Atrial fibrillation

Yes (%)

16 (6.3%)

2 (3.8%)

0.748

Primary tumor size (cm)

Median (range)

3 (0.4-14)

3.6 (0.8-11)

0.912

Primary tumor location (lobe)

Upper (%)

152 (59.6%)

26 (50.0%)

0.02

Lower (%)

89 (34.9%)

17 (32.7%)

Middle (%)

14 (5.5%)

9 (17.3%)

Histology (type)

Adenocarcinoma (%)

180 (70.6%)

46 (88.5%)

0.028

Squamous carcinoma (%)

58 (22.7%)

5 (9.6%)

Other (%)

17 (6.7%)

1 (1.9%)

CI

Yes (%)

160 (62.7%)

44 (84.6%)

0.002

T status

T3-T4 (%)

74 (29.0%)

28 (53.8%)

0.001

LN status

N2-N3 (%)

134 (52.5%)

42 (80.8%)

<0.001

D-D (ng/ml)

Median (range)

182 (0.11-14612)

304.5 (52-7640)

<0.001

CEA (ng/ml)

Median (range)

4.11 (0.1-746.7)

9.675 (1.28-1068)

<0.001

CA125 (U/ml)

Median (range)

19.44 (3.1-2846)

49.15 (6.61-796.7)

<0.001

CYFRA21-1 (ng/ml)

Median (range)

21.93 (0.3-971)

28.56 (1.36-978)

0.23

BM: brain metastasis; BMI: body mass index; CI: cerebral infarction; D-D: D-Dimer; CEA: carcinoembryonic antigen; CA125: carbohydrate antigen 125; CYFRA21-1: cytokeratin 19 fragment.